Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Routine UK Funding OKd For Tagrisso In First & Second-Line NSCLC

Executive Summary

Health technology assessment body NICE has published two final guidance documents that cover the use of AstraZeneca’s drug at different points in the treatment pathway for locally advanced or metastatic EGFR-positive non-small cell lung cancer.

You may also be interested in...



AstraZeneca To Fight NICE Knockback For Tagrisso In England

Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel